Physician profile
Margaret Scully
NPI 1528145570
$4,574.84
in general payments reported to CMS, 2019-2025
16 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $379 · 2021: $607 · 2022: $601 · 2023: $608 · 2024: $753 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,660.16 | 2023-2025 | Botox |
| Merz North America, INC. | $1,198.40 | 2019-2025 | |
| Allergan, INC. | $906.83 | 2019-2022 | |
| Pfizer INC. | $251.81 | 2019-2022 | |
| Galderma Laboratories, L.P. | $176.71 | 2019-2024 | |
| Janssen Biotech, INC. | $78.22 | 2022-2023 | Simponi Aria, Remicade, Simponi |
| Genzyme Corporation | $59.93 | 2019-2022 | |
| Epi Health, LLC | $47.75 | 2019 | |
| Lilly USA, LLC | $47.50 | 2020-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.54 | 2021 | |
| Biofrontera INC. | $24.12 | 2025 | |
| Mayne Pharma Commercial LLC | $24.02 | 2019 | |
| Amgen INC. | $22.11 | 2023 | Otezla |
| Incyte Corporation | $17.83 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.71 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $17.20 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Scully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.